Analyzing protein levels in urine through clinical testing is crucial when evaluating kidney health and treatment outcomes in patients with lupus nephritis. Yet in certain instances, the presence or absence of kidney inflammation may not affect proteinuria levels, which can give clinicians an inaccurate portrayal of kidney health. Postdoctoral fellow and clinician-scientist Andrea Fava discusses the discovery of urine biomarkers that can accurately detect the effectiveness of lupus nephritis treatments earlier than normal proteinuria testing. He’ll be leading an oral presentation at this year’s American College of Rheumatology 2022 annual conference.

Read the abstract: https://acrabstracts.org/abstract/aut...